Epidemiologic studies suggest that genetic factors confer a predisposition to the formation of renal calcium stones or bone demineralization. Low serum phosphate concentrations due to a decrease in renal phosphate reabsorption have been reported in some patients with these conditions, suggesting that genetic factors leading to a decrease in renal phosphate reabsorption may contribute to them. We hypothesized that mutations in the gene coding for the main renal sodium–phosphate cotransporter (NPT2a) may be present in patients with these disorders.
Inositol 1,4,5-trisphosphate receptors (IP 3 Rs) release calcium ions, Ca 2+ , from intracellular stores, but their roles in mediating Ca 2+ entry are unclear. IP 3 stimulated opening of very few (1.9 ± 0.2 per cell) Ca 2+ -permeable channels in whole-cell patch-clamp recording of DT40 chicken or mouse B cells. Activation of the B cell receptor (BCR) in perforated-patch recordings evoked the same response. IP 3 failed to stimulate intracellular or plasma membrane (PM) channels in cells lacking IP 3 R. Expression of IP 3 R restored both responses. Mutations within the pore affected the conductances of IP 3 -activated PM and intracellular channels similarly. An impermeant pore mutant abolished BCR-evoked Ca 2+ signals, and PM IP 3 Rs were undetectable. After introduction of an α-bungarotoxin binding site near the pore, PM IP 3 Rs were modulated by extracellular α-bungarotoxin. IP 3 Rs are unusual among endoplasmic reticulum proteins in being also functionally expressed at the PM, where very few IP 3 Rs contribute substantially to the Ca 2+ entry evoked by the BCR.
In chronic kidney disease (CKD), proteinuria results in severe tubulointerstitial lesions, which ultimately lead to end-stage renal disease. Here we identify 4-phenylbutyric acid (PBA), a chemical chaperone already used in humans, as a novel therapeutic strategy capable to counteract the toxic effect of proteinuria. Mechanistically, we show that albumin induces tubular unfolded protein response via cytosolic calcium rise, which leads to tubular apoptosis by Lipocalin 2 (LCN2) modulation through ATF4. Consistent with the key role of LCN2 in CKD progression, Lcn2 gene inactivation decreases ER stress-induced apoptosis, tubulointerstitial lesions and mortality in proteinuric mice. More importantly, the inhibition of this pathway by PBA protects kidneys from morphological and functional degradation in proteinuric mice. These results are relevant to human CKD, as LCN2 is increased in proteinuric patients. In conclusion, our study identifies a therapeutic strategy susceptible to improve the benefit of RAS inhibitors in proteinuria-induced CKD progression.
In Arabidopsis suspension cells a rapid plasma membrane depolarization is triggered by abscisic acid (ABA). Activation of anion channels was shown to be a component leading to this ABA-induced plasma membrane depolarization. Using experiments employing combined voltage clamping, continuous measurement of extracellular pH, we examined whether plasma membrane H+-ATPases could also be involved in the depolarization. We found that ABA causes simultaneously cell depolarization and medium alkalinization, the second effect being abolished when ABA is added in the presence of H+ pump inhibitors. Inhibition of the proton pump by ABA is thus a second component leading to the plasma membrane depolarization. The ABA-induced depolarization is therefore the result of two different processes: activation of anion channels and inhibition of H+-ATPases. These two processes are independent because impairing one did not suppress the depolarization. Both processes are however dependent on the [Ca2+]cyt increase induced by ABA since increase in [Ca2+]cyt enhanced anion channels and impaired H+-ATPases.
Inositol 1,4,5-trisphosphate receptors (IP3Rs) are ubiquitous intracellular Ca2+ channels. IP3 binding to the IP3-binding core (IBC) near the N terminus initiates conformational changes that lead to opening of a pore. The mechanisms underlying this process are unresolved. We synthesized 2-O–modified IP3 analogs that are partial agonists of IP3R. These are similar to IP3 in their interactions with the IBC, but they are less effective than IP3 in rearranging the relationship between the IBC and the N-terminal suppressor domain (SD), and they open the channel at slower rates. IP3R with a mutation in the SD occupying a position similar to the 2-O substituent of the partial agonists has a reduced open probability that is similar for full and partial agonists. Bulky or charged substituents from either the ligand or the SD therefore block obligatory coupling of the IBC and the SD. Analysis of ΔG for ligand binding shows that IP3 is recognized by the IBC and conformational changes then propagate entirely via the SD to the pore.
Galectin-9 (gal-9) is a multifunctional β-galactoside-binding lectin, frequently released in the extra-cellular medium, where it acts as a pleiotropic immune modulator. Despite its overall immunosuppressive effects, a recent study has reported a bimodal action of gal-9 on human resting blood T cells with apoptosis occurring in a majority of them, followed by a wave of activation and expansion of Th1 cells in the surviving population. Our knowledge of the signaling events triggered by exogenous gal-9 in T cells remains limited. One of these events is a cytosolic calcium (Ca2+) release reported in some murine and human T cells. The aim of this study was to investigate the contribution of Ca2+ mobilization to apoptotic and non-apoptotic effects of exogenous gal-9 in human T cells. We found that the T cell receptor (TCR)/CD3 complex and the Lck kinase were required for Ca2+ mobilization but not for apoptosis induction in Jurkat cells. These data were confirmed in human CD4+ T cells from peripheral blood: a specific Lck chemical inhibitor abrogated Ca2+ mobilization, but not apoptosis induction. Moreover, Lck activity was also required for the production of Th1-type cytokines, i.e. interleukine-2 and interferon-γ, which resulted from gal-9 stimulation in peripheral CD4+ T cells. These findings indicate that gal-9 acts on T cells by two distinct pathways: one mimicking antigen-specific activation of the TCR with a mandatory contribution of proximal elements of the TCR complex, especially Lck, and another resulting in apoptosis which is independent of this complex.